日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細


公開

学術論文

Metabolic changes in quinolinic acid-lesioned rat striatum measured non-invasively by in vivo 1H NMR spectroscopy

MPS-Authors
There are no MPG-Authors in the publication available
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
フルテキスト (公開)
公開されているフルテキストはありません
付随資料 (公開)
There is no public supplementary material available
引用

Tkac, I., Keene, C., Pfeuffer, J., Low, W., & Gruetter, R. (2001). Metabolic changes in quinolinic acid-lesioned rat striatum measured non-invasively by in vivo 1H NMR spectroscopy. Journal of Neuroscience Research, 66(5), 891-898. doi:10.1002/jnr.10112.


引用: https://hdl.handle.net/11858/00-001M-0000-0013-E338-D
要旨
Intrastriatal injection of quinolinic acid (QA) provides an animal model of Huntington disease. In vivo (1)H NMR spectroscopy was used to measure the neurochemical profile non-invasively in seven animals 5 days after unilateral injection of 150 nmol of QA. Concentration changes of 16 metabolites were measured from 22 microl volume at 9.4 T. The increase of glutamine ((+25 +/- 14), mean +/- SD, n = 7) and decrease of glutamate (-12 +/- 5), N-acetylaspartate (-17 +/- 6), taurine (-14 +/- 6) and total creatine (-9 +/- 3) were discernible in each individual animal (P < 0.005, paired t-test). Metabolite concentrations in control striata were in excellent agreement with biochemical literature. The change in glutamate plus glutamine was not significant, implying a shift in the glutamate-glutamine interconversion, consistent with a metabolic defect at the level of neuronal-glial metabolic trafficking. The most significant indicator of the lesion, however, were the changes in glutathione ((-19 +/- 9), P < 0.002)), consistent with oxidative stress. From a comparison with biochemical literature we conclude that high-resolution in vivo (1)H NMR spectroscopy accurately reflects the neurochemical changes induced by a relatively modest dose of QA, which permits one to longitudinally follow mitochondrial function, oxidative stress and glial-neuronal metabolic trafficking as well as the effects of treatment in this model of Huntington disease.